Generex Biotechnology breaks down acquisitions of FY 2019

Written by Alan Condon | July 10, 2019 | Print  |

Generex Biotechnology provided an overview of the company's fiscal year ending July 31, 2019, with a string of acquisitions taking center stage.

Four insights:

1. Generex acquired 61 percent of Olaregen Therapeutix. The company's Excellagen wound care product is a 3D wound conforming model.

2. The company acquired regenerative medicine company Regentys, which developed a non-surgical treatment option for Ulcerative Colitis — ExtraCellular Matrix Hydrogel.

3. The company also acquired Veneto Assets, Pantheon Medical, Kiromonic and MediSource Partners and completed the 100 percent acquisition of HDS, which is now called NuGenerix Diagnostics.

4. In April 2019, Generex bolstered its board of directors with two independent appointments, Mark Prioletti and Omar Gzouli.

More articles on devices:
Cerapedics expands Colorado HQ — 3 things to know
HSS acquires low-dose orthopedic imaging system — 3 insights
Medtronic secures market-leading position through Titan Spine acquisition, analyst says



© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months